Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscular Atrophy × Cyproheptadine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Optic Nerve Glioma 2 Oligodendroglioma 2 Neoplasms 2 Myelodysplastic Syndromes 2 Medulloblastoma 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma 2 Leukemia 2 Familial ependymoma 2 Dendritic Cell Sarcoma, Interdigitating 2 Choroid Plexus Neoplasms 2 Cachexia 2 Burkitt Lymphoma 2 Body Weight Changes 2 Astrocytoma 2 Wilms Tumor 1 Vomiting 1 Testicular Neoplasms 1 Spinal Cord Neoplasms 1 Sarcoma, Ewing 1 Sarcoma, Endometrial Stromal 1 Sarcoma 1 Ovarian Germ Cell Cancer 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasms, Neuroepithelial 1 Nausea 1

Interventions

rimabotulinumtoxinB 1 ostarine 1 Standard of Care 1 Olanzapine 1 Enteral Nutrition 1 Eicosapentaenoic Acid 1 Diet Therapy 1 Cyproheptadine 1 Creatine 1 Carnitine 1 Botulinum Toxins, Type A 1 Acetylcysteine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06175273 2025-09-18

POINT

University of Kentucky

Phase 2/3 Completed

Muscular Atrophy, Neoplasms, Child Nutrition Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡